Articles On ImpediMed (ASX:IPD)

Healthcare and life sciences expert Scott Power – a senior analyst with Morgans Financial for 24 years – on what the movers and shakers have been doing in health and which ASX health stocks make Scott’s Powerplays. Look in the mirror and li...

ImpediMed (IPD) has welcomed a second contract extension and expansion of its SOZO Digital Health Platform for use in clinical trials being conducted for AstraZeneca The phase two trial will use the SOZO devices to track patient fluid volu...

In this week’s ScoPo’s Powerplays, healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, examines the turbulent start to 2022 for ASX health stocks and what could lie ahead as ge...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. First a note on things are are...

At the time of writing, the ASX 200 Health Index (XHJ) is down 2%, while the benchmark ASX 200 is also falling by 0.75%. The path is now open for pharma distributor Australian Pharmaceutical Industries (ASX: API) to be acquired by Wesfarmer...

ImpediMed (IPD) announces clinical trial agreement for its SOZO platform, which helps patients with end stage renal disease by assisting with removing fluid during dialysis The company has entered into the agreement with Balboa Research a...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Everyone loves a comeback. Just...

ImpediMed (IPD) sees its PREVENT Trial results peer-reviewed and published ImpediMed’s study demonstrated intervention in patients with early detection of cancer-related lymphoedema using its L-Dex technology can result in a lower rate of...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 25 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week It’s been a...

Trading Places is Stockhead’s recap of the buys and sells of ASX small cap shares by fund managers and other famous investors over the last fortnight. Specifically, Stockhead tracks substantial shareholder movements, being shareholders hold...

Highlights The rising population and the rise in health issues are increasing the demand for healthcare products and services. People’s lifestyle is one of the reasons for rising health issues in the present times. TLX, RHT, CYC, IPD,...

ImpediMed (IPD) completes its share purchase plan, heavily oversubscribed by more than $27 million The share purchase plan (SPP) closed on November 12 and saw applications totalling over $32 million – well in excess of the company’s target...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week At the time...

It was a mixed bag of results for ASX healthcare shares as we walked through October, as some names came in red hot, whilst others missed the mark completely. After a sharp downturn in late September, where it lost around 7% in just one w...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Theme of the week With a slew o...

The Impedimed Limited (ASX: IPD) share price has come out of a trading halt today to backtrack mid-afternoon. This comes after the medical technology company provided an update on its recent equity raise. At the time of writing, Impedimed...

The ASX finished in the green by just 0.03%. Today’s gain was spurred by a 1.34% rally in tech shares as well as a rally in Crown (ASX:CWN) shares in the wash-up of the Victorian government’s royal commission. Despite the report finding the...

Market watchers interested in the Impedimed Limited (ASX: IPD) share price have woken to another frosty session as the company’s stock remains frozen for a second day. Impedimed’s shares were halted from trade yesterday while the company u...

The ASX is off to a positive start this week, putting its total gains over the past three weeks up to about 3.6%. The ASX 200 closed 0.34% higher – at 7,441 points. Spurring today’s gains was energy with a 2.64% gain while resources and uti...

ImpediMed is launching a capital raise on Monday morning, on the back of positive clinical trial results last week.

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Power says...

As the world emerges from the pandemic, markets are now contending with an energy crisis, a global shipping glut and the prospect of central banks starting to raise interest rates. But so far this week, investors are shrugging it all off as...

Just like yesterday the ASX rallied for most of the day but retreated in the afternoon and today closed in the red. The ASX 200 was down 0.08% at 7,375 points. Another difference from yesterday was tech was the best sector gaining 1.7% whil...

The Impedimed Limited (ASX: IPD) share price is making good ground today, having climbed 10% from the market open to now trade at 16.5 cents. Impedimed shares are again on the move after coming out of a trading halt that was requested bef...

ImpediMed (IPD) has rounded off its PREVENT trial, successfully meeting its primary end point in the largest recorded trial to assess lymphoedema prevention The findings were based on a 1,200-person trial over six and a half years, spannin...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week At the time...

Wall Street mixed as ‘debt ceiling’ deadline approaches US stock markets finished in mixed territories on Thursday, as a last session selloff turned the Nasdaq from positive to negative at the close. The Dow Jones rose by 0.26%, the S&P...

The Impedimed Limited (ASX: IPD) share price is on the move during mid-afternoon trade. This comes as the medical technology company announced a positive update in regards to its SOZO Heart Failure Program. At the time of writing, Impedime...

Wall Street mixed to end a volatile week The three US stock marker benchmarks finished the week in mixed territories on Friday, after a volatile week of trading. The Dow Jones rose by 0.1%, S&P 500 by 0.15%, but the tech heavy Nasdaq sl...

Wall Street falls again for fourth consecutive day All three major US stock market benchmarks fell on Friday for the fourth consecutive day. Equity investors are concerned about the rising Delta variant cases, and the impending Fed tapering...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Healthcare...

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((ACF)) - Acrow Formwork and Construction Services ((ABC)) - AdBri ((APT)) - Afterpay ((APA)) - APA Group ((AMI)) - Aurelia Metals ((AOF)) - Australian Unity Office Fund (...

Today, Thursday the 26th of August, we are happy to buy Lovisa (ASX:LOV), Zip Co Ltd (ASX:Z1P), Oil Search Ltd (ASX:OSH), Idp Education Ltd (ASX:IEL), Dalrymple Bay (ASX:DBI), Universal Store (ASX:UNI), Acrow Formwork (ASX:ACF), Wagners Hld...

The Impedimed Limited (ASX: IPD) share price is appreciating after the company released its full-year results for FY21. At the time of writing, shares in the healthcare company are trading for 13 cents each – up 4%. For context, the ASX Al...

The ASX 200 health stocks index (XHJ) rose by 0.60% this morning, compared to the broader index which climbed by 0.40% Biopharmaceutical company Dimerix (ASX:DXB) announced that it has commenced ACTION3, a Phase III study in patients with f...

IDT Australia (ASX:IDT) jumped more than 20% after announcing that it has formalised activities with the Australian Government to potentially assist with the production of a COVID-19 vaccine. There was recent media interest surrounding a mR...

Wall Street rose ahead of world centrals banks meeting this week All three US stock market indexes bounced back on Friday, ahead of this week’s Jackson Hole Economic Policy Symposium, a virtual meeting of world central banks leaders held be...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Healthcare...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Healthcare...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Healthcare...

ImpediMed (IPD), The A2 Milk Company (A2M), Unibail-Rodamco-Westfield (URW), Harvey Norman Holdings (HVN) & IDP Education (IEL).

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week As we appro...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Healthcare...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Themes of the week Healthcare f...

The market is trading near day’s high at the close, after the Reserve Bank of Australia’s (RBA) maintained status quo in its latest policy announcement and upgraded the country’s GDP growth estimates. The benchmark index ASX 200 was up 35.5...

The Impedimed Limited (ASX: IPD) share price is bouncing this morning after the company announced positive progress in its SOZO technology for heart patients.  The Impedimed share price has been seesawing between the opening price of 12 ce...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Healthcare...

The Impedimed Limited (ASX: IPD) share price was off to a flying start this morning, up 13% at market open. The positive price movement came as the medical technology company announced it received Food and Drug Administration (FDA) clearan...